The global buccal drug delivery systems market size is expected to reach USD 6.56 billion by 2030, according to a new report. The market is expected to grow at a CAGR of 6.2% from 2024 to 2030. Buccal drug delivery systems have gained significant momentum since the last decade. Elimination of first-pass metabolism, quick absorption of the pH-sensitive drug, no interaction with stomach acid, quicker onset of action than any oral dose, minimal side effects, and reduced drug degradation are some of the factors fueling the market growth. Buccal drug delivery has gained large acceptance among geriatric patients and patients having difficulty swallowing.
Leading players like Generex, NovaDel, Biodiversity Sciences International, and Transcept Pharmaceuticals are constantly developing critical drugs like insulin, heparin, morphine, long-lasting pain analgesics, and some anti cardiac drugs into rapid mists, mucoadhesive discs, and lozenges. Commercialization of this research would eventually lead to being a major life savior as it would ensure the faster onset of action and eliminate drug degradation. Despite the increased R&D activity among market players, asteep decline was observed in the sales and revenue gainsdue to the outbreak of the COVID-19 pandemic. Except for covid medications, several other drug markets were majorly hit leading to the dip in the market for buccal drug delivery. However, it is expected to bounce back by 2022.
This product will be delivered within 2 business days.
Leading players like Generex, NovaDel, Biodiversity Sciences International, and Transcept Pharmaceuticals are constantly developing critical drugs like insulin, heparin, morphine, long-lasting pain analgesics, and some anti cardiac drugs into rapid mists, mucoadhesive discs, and lozenges. Commercialization of this research would eventually lead to being a major life savior as it would ensure the faster onset of action and eliminate drug degradation. Despite the increased R&D activity among market players, asteep decline was observed in the sales and revenue gainsdue to the outbreak of the COVID-19 pandemic. Except for covid medications, several other drug markets were majorly hit leading to the dip in the market for buccal drug delivery. However, it is expected to bounce back by 2022.
Buccal Drug Delivery Systems Market Report Highlights
- The buccal tablets and lozenges type segment accounted for the largest revenue share in 2023 due to its wider acceptance among patients
- The smoking cessation application segment held the largest share in 2023. Buccal drug delivery is often the most preferred and effective formulation for treating patients with smoking or nicotine addiction
- The hospital end-user segment captured the largest revenue share in 2023 owing to a large number of admissions of geriatric patients and abundant medication supplies
- North America held the largest revenue share in 2023 due to a large number of leading manufacturers and growing research in the region
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Buccal Drug Delivery Systems Market Variables, Trends, & Scope
Chapter 4. Buccal Drug Delivery Systems Market: Type Estimates & Trend Analysis
Chapter 5. Buccal Drug Delivery Systems Market: Application Estimates & Trend Analysis
Chapter 6. Buccal Drug Delivery Systems Market: End Use Estimates & Trend Analysis
Chapter 7. Buccal Drug Delivery Systems Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
Companies Mentioned
- Teva Pharmaceutical Industries Ltd.
- GSK plc
- Pfizer Inc.
- Generex Biotechnology Corporation (LUMITOS AG)
- ARx, LLC.
- Catalent, Inc
- Collegium Pharmaceutical
- Cynapsus Therapeutics Inc.
- Endo, Inc.
- Indivior PLC
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | July 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 4.23 Billion |
| Forecasted Market Value ( USD | $ 6.56 Billion |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
